 Home > Active Ingredient News > Blood System > NEJM: Comparison of Tisagenlecleucel or standard of care in aggressive B-cell lymphoma

NEJM: Comparison of Tisagenlecleucel or standard of care in aggressive B-cell lymphoma

 Last Update: 2022-03-05
 Source: Internet
 Author: User

Tags

fbs cell culture

1 2 5 6

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Patients with aggressive B-cell non-Hodgkin lymphoma who do not respond or progress within 12 months of first-line therapy have poorer outcomes
.

Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatments

lymphoma

In a study published today in the top medical journal NEJM, researchers conducted an international Phase 3 trial involving patients with aggressive lymphoma who did not respond or progressed within 12 months of first-line therapy
.

Patients were randomly assigned to receive Tisagenlecleucel in combination with optional bridging therapy (Tisagenlecleucel arm) or salvage chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) (standard care arm)
.

The primary endpoint of the study was event-free survival, defined as the time from randomization to stable or progressive disease at or after the Week 12 assessment or death

stem cell

A total of 322 patients were randomized in the study
.

At baseline, the Tisagenlecleucel group had a higher percentage of patients with high-grade lymphoma than the standard-care group (24.

CONCLUSIONS: Tisagenlecleucel is not superior to standard therapy in patients with aggressive B-cell non-Hodgkin lymphoma
.

More research is needed to assess which patients would benefit most from each approach

Tisagenlecleucel was not superior to standard therapy in patients with aggressive B-cell non-Hodgkin lymphoma

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Pharmaceutical Grade 99% 2-Deoxy-D-ribose CAS: 533-67-5 Best Quality

CAS No.: 533-67-5

Pharmacy Grade;

$385-465/KG FOB

Best Quality 99% Semaglutide Semaglutide, Reta, AOD CAS:910463-68-2/782487-28-9 for Weight Loss

CAS No.: 910463-68-2

Pharmacy Grade;

$250-280/G FOB

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

CAS No.: 204656-20-2

Pharmacy Grade

$200-250/G FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.